Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects
- PMID: 28700655
- PMCID: PMC5507312
- DOI: 10.1371/journal.pone.0181086
Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects
Abstract
Fatigue is the symptom most commonly reported by long-term cancer survivors and is increasingly recognized as related to skeletal muscle dysfunction. Traditional chemotherapeutic agents can cause acute toxicities including cardiac and skeletal myopathies. To investigate the mechanism by which chemotherapy may lead to persistent skeletal muscle dysfunction, mature adult mice were injected with a single cyclophosphamide dose and evaluated for 6 weeks. We found that exposed mice developed a persistent decrease in treadmill running time compared to baseline (25.7±10.6 vs. 49.0±16.8 min, P = 0.0012). Further, 6 weeks after drug exposure, in vivo parameters of mitochondrial function remained below baseline including maximum ATP production (482.1 ± 48.6 vs. 696.2 ± 76.6, P = 0.029) and phosphocreatine to ATP ratio (3.243 ± 0.1 vs. 3.878 ± 0.1, P = 0.004). Immunoblotting of homogenized muscles from treated animals demonstrated a transient increase in HNE adducts 1 week after exposure that resolved by 6 weeks. However, there was no evidence of an oxidative stress response as measured by quantitation of SOD1, SOD2, and catalase protein levels. Examination of mtDNA demonstrated that the mutation frequency remained comparable between control and treated groups. Interestingly, there was evidence of a transient increase in NF-ĸB p65 protein 1 day after drug exposure as compared to saline controls (0.091±0.017 vs. 0.053±0.022, P = 0.033). These data suggest that continued impairment in muscle and mitochondria function in cyclophosphamide-treated animals is not linked to persistent oxidative stress and that alternative mechanisms need to be considered.
Conflict of interest statement
Figures






Similar articles
-
Skeletal muscle mitochondrial adaptations induced by long-term cigarette smoke exposure.Am J Physiol Endocrinol Metab. 2021 Jul 1;321(1):E80-E89. doi: 10.1152/ajpendo.00544.2020. Epub 2021 Jun 14. Am J Physiol Endocrinol Metab. 2021. PMID: 34121449 Free PMC article.
-
Two weeks of metformin treatment enhances mitochondrial respiration in skeletal muscle of AMPK kinase dead but not wild type mice.PLoS One. 2013;8(1):e53533. doi: 10.1371/journal.pone.0053533. Epub 2013 Jan 14. PLoS One. 2013. PMID: 23341947 Free PMC article.
-
Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.Eur J Pharmacol. 2014 Oct 5;740:690-6. doi: 10.1016/j.ejphar.2014.06.008. Epub 2014 Jun 22. Eur J Pharmacol. 2014. PMID: 24964389
-
Loss of the antioxidant enzyme CuZnSOD (Sod1) mimics an age-related increase in absolute mitochondrial DNA copy number in the skeletal muscle.Age (Dordr). 2016 Aug;38(4):323-333. doi: 10.1007/s11357-016-9930-1. Epub 2016 Jul 21. Age (Dordr). 2016. PMID: 27444179 Free PMC article.
-
Mitochondrial Dysfunction as an Underlying Cause of Skeletal Muscle Disorders.Int J Mol Sci. 2022 Oct 26;23(21):12926. doi: 10.3390/ijms232112926. Int J Mol Sci. 2022. PMID: 36361713 Free PMC article. Review.
Cited by
-
Associations between mitochondrial copy number, exercise capacity, physiologic cost of walking, and cardiac strain in young adult survivors of childhood cancer.J Cancer Surviv. 2024 Aug;18(4):1154-1167. doi: 10.1007/s11764-024-01590-7. Epub 2024 Apr 18. J Cancer Surviv. 2024. PMID: 38635100 Free PMC article.
-
A clinically relevant combination treatment with doxorubicin and cyclophosphamide does not induce hepatotoxicity in C57BL/6J mice.Liver Res. 2021 Dec;5(4):239-242. doi: 10.1016/j.livres.2021.04.002. Epub 2021 May 7. Liver Res. 2021. PMID: 34900377 Free PMC article.
-
A Similar Metabolic Profile Between the Failing Myocardium and Tumor Could Provide Alternative Therapeutic Targets in Chemotherapy-Induced Cardiotoxicity.Front Cardiovasc Med. 2018 Jun 11;5:61. doi: 10.3389/fcvm.2018.00061. eCollection 2018. Front Cardiovasc Med. 2018. PMID: 29951485 Free PMC article. No abstract available.
-
Concurrence of osteonecrosis and steroid myopathy secondary to oral steroid therapy in a patient with ABCB1 gene polymorphisms: A case report.Front Endocrinol (Lausanne). 2022 Oct 7;13:1016687. doi: 10.3389/fendo.2022.1016687. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36277691 Free PMC article.
-
Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers.Front Cell Dev Biol. 2021 Sep 14;9:719643. doi: 10.3389/fcell.2021.719643. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34595171 Free PMC article. Review.
References
-
- Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet. 2003;362:640–50. doi: 10.1016/S0140-6736(03)14186-4 - DOI - PubMed
-
- al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs. 2001;2(3):186–97. doi: 10.1177/109980040100200304 - DOI - PubMed
-
- Banthia R, Malcarne VL, Roesch SC, Ko CM, Greenbergs HL, Varni JW, et al. Correspondence between daily and weekly fatigue reports in breast cancer survivors. J Behav Med. 2006;29(3):269–79. doi: 10.1007/s10865-006-9053-8 - DOI - PubMed
-
- Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, et al. Cancer-related fatigue. J Natl Compr Canc Netw. 2010;8(8):904–31. - PubMed
-
- Calvani R, Joseph AM, Adhihetty PJ, Miccheli A, Bossola M, Leeuwenburgh C, et al. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biol Chem. 2013;394(3):393–414. doi: 10.1515/hsz-2012-0247 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous